肌肉炎的临床终点:挑战和前进的途径
Cristina Ricco1,2, Caroline J Stone1,2, Victoria P Werth1,2
1Corporal Michael J. Crescenz VA Medical Center.
Current opinion in rheumatology
|August 22, 2024
概括
新的临床结果措施通过评估肌肉和皮肤疾病活动来改善肌肉炎试验. 肌肉和皮肤皮质神经炎结果 (DMOMS) 措施提高了患者的包容性和治疗策略.
科学领域:
- 类风湿病学 类风湿病学
- 临床试验 临床试验
- 结果措施 结果措施
背景情况:
- 肌肉炎临床试验在全面评估疾病活性方面面临挑战.
- 传统的结果指标,如总改善指标 (TIS),无法充分捕捉皮肤的参与,特别是皮肤肌炎 (DM).
研究的目的:
- 审查肌肉炎临床终点方面的进展,重点关注肌肉和皮肤疾病活动的综合评估.
- 突出新结果措施对临床试验设计和患者包容性的影响.
主要方法:
- 审查最近的研究和临床试验数据.
- 分析传统和新型的结果指标,包括皮肤疾病区域和严重性指数 (CDASI) 和肌肉和皮肤肌肉炎结果 (DMOMS).
主要成果:
- 像TIS这样的传统措施对皮肤占主导地位的DM有局限性.
- 皮肤特异性测量 (CDASI) 和复合测量 (DMOMS) 提供了更平衡的疾病活性评估.
- 临床试验数据显示,使用这些新型措施在经典和骨髓病性DM中都有好处.
结论:
- 结果测量的进展对于包容性和有效的肌炎临床试验至关重要.
- 结合像DMOMS这样的全面工具,可以改善肌肉和皮肤疾病活动的评估.
- 这一转变对于解决所有异形性炎症性肌肉病患者的需求至关重要,包括那些皮肤占主导地位的DM患者.
更多相关视频
14:10Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies
Published on: January 31, 2013
32.9K
04:01Author Spotlight: Advanced Integrated Model for Sepsis-Induced Myopathy and Single-Cell Metabolic Analysis
Published on: June 14, 2024
655
相关概念视频
01:15Myasthenia Gravis: Diagnostic Tests
709
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
709
01:20Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K